Insmed (NASDAQ:INSM) and Adamas Pharmaceuticals (NASDAQ:ADMS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider & Institutional Ownership

89.6% of Adamas Pharmaceuticals shares are owned by institutional investors. 3.9% of Insmed shares are owned by company insiders. Comparatively, 24.6% of Adamas Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares Insmed and Adamas Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Insmed N/A -81.18% -45.16%
Adamas Pharmaceuticals -617.27% -106.74% -51.66%

Earnings & Valuation

This table compares Insmed and Adamas Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Insmed N/A N/A -$192.64 million ($2.89) -8.62
Adamas Pharmaceuticals $570,000.00 430.18 -$89.49 million ($3.97) -2.26

Adamas Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Adamas Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Insmed and Adamas Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed 0 2 5 0 2.71
Adamas Pharmaceuticals 0 2 7 0 2.78

Insmed presently has a consensus price target of $34.50, suggesting a potential upside of 38.55%. Adamas Pharmaceuticals has a consensus price target of $30.71, suggesting a potential upside of 242.41%. Given Adamas Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Adamas Pharmaceuticals is more favorable than Insmed.

Volatility & Risk

Insmed has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500. Comparatively, Adamas Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.


Adamas Pharmaceuticals beats Insmed on 8 of the 13 factors compared between the two stocks.

About Insmed

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's product candidates under development includes ADS-5102, which is in Phase III clinical trials for the treatment of multiple sclerosis walking impairment; and in Phase II clinical trials for additional indications, such as the treatment of wearing OFF and delaying motor complications in Parkinson's disease, tardive dyskinesia, Huntington's chorea, and Tourette syndrome, as well as non-motor disorders consisting of depression, and anti-psychotic induced weight gain. Its products under development also includes ADS-4101, a modified-release lacosamide that has completed Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with's FREE daily email newsletter.